Tech Company Financing Transactions
Proclara Biosciences Funding Round
Proclara Biosciences, operating out of Cambridge, secured $6.4 million in funding from bioMerieux, Shire Strategic Investment Group and private investors.
Transaction Overview
Company Name
Announced On
5/6/2013
Transaction Type
Venture Equity
Amount
$6,400,000
Round
Undisclosed
Investors
bioMerieux (Lead Investor) (Valerie Calenda)
Proceeds Purpose
The new funds will help support ongoing pre-IND studies for lead compound NPT002 and will advance the development of second-generation fusion proteins with the potential for treating several neurodegenerative conditions including Alzheimer's, Parkinson's and Huntington's diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
125 Cambridgepark Dr. 301
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Not Recorded
Overview
Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Suzanne Bruhn
Chief Medical Officer
David Michelson
Chief Scientific Officer
Richard Fisher
VP - Manufacturing
Jason Wright
VP - Operations
Kelly Magnuson
VP - R & D
Rajaraman Krishnan
VP - R & D
Jonathan Levenson
VP - Regulatory Affairs
Roxanne Bales
Browse more venture capital transactions:
Prev: 5/6/2013: Nanostim venture capital transaction
Next: 5/6/2013: Clustrix venture capital transaction
Share this article
News on VC Transactions
We report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs